brexucabtagene autoleucel
brexucabtagene autoleucel is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including TECARTUS. Available dosage form: suspension.
Drug Details
- Generic Name
- brexucabtagene autoleucel
- Brand Names
- TECARTUS
- Application Number
- BLA125703
- Sponsor
- Kite Pharma, Inc.
- NDC Codes
- 2
- Dosage Forms
- SUSPENSION
- Routes
- INTRAVENOUS
- Active Ingredients
- BREXUCABTAGENE AUTOLEUCEL
Indications and Usage
1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 1.2 Acute Lymphoblastic Leukemia TECARTUS is indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).